Cutting Edge Dialysis Therapy: Regenerative Healing in AV Access

Vascular surgeon and V007 clinical trial investigator Dr. John Lane of UC San Diego Medical School and VA San Diego discusses the vast potential of Human Acellular Vessel (HAV) for people living with end-stage renal disease, calling it the “holy grail” of vascular research topics in the last twenty years.
Humacyte's Human Acellular Vessel (HAV) product is investigational and has not been approved by the FDA or other regulatory authorities. Humacyte is studying the safety and effectiveness of the HAVs in clinical trials.
Learn more at www.Humacyte.com

[@KrackerJack5586]

Thank you so much for doing this it really helps all of us understand the process the company and the hope for the future

[@LoCoLeaderDK]

Dont play music please...